Psoriatic Arthritis
Introduction to PsA
Key Cell Types and Activated Pathways in Psoriatic Arthritis
Role of IL-17 Signaling
Pharmacologic Agents Indicated for the Treatment of PsA
FUTURE 1 Efficacy and Safety of Secukinumab
FUTURE 2 Efficacy and Safety of SC Secukinumab
FUTURE 2: Efficacy of Secukinumab in Anti-TNF-Naive and Anti-TNF-IR Patients
FUTURE 5 Improvement in Radiographic Progression
Summary of Pooled Safety Across FUTURE 1 and FUTURE 2 Studies
Ixekizumab for the Treatment of PsA SPIRIT-P1 Results
SPIRIT-P2 Ixekizumab for the Treatment of PsA in TNF-IR Patients
Frequency of AEs Across SPIRIT-P1 and SPIRIT-P2 Studies
SPIRIT-H2H: Study Comparing Safety and Efficacy of Ixekizumab and Adalimumab in PsA
SPIRIT-H2H Results Primary and Secondary Outcomes at Week 24
Safety and Efficacy of Bimekizumab in Patients With PsA
GRAPPA Treatment Scheme
Enthesitis in PsA
IL-17 Inhibitors in the Treatment of Enthesitis
Dactylitis in PsA
IL-17 Inhibitors in the Treatment of Dactylitis
MAXIMISE Trial Managing Axial Manifestations in Patients with PsA
Concluding Remarks
Abbreviations
Abbreviations (cont)
Abbreviations (cont)